Kwadwo Darko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kwadwo Darko has a total of 325 co-authors. Here are the top co-authors by number of shared publications:
Umaru Barrie
LCEN Consortium, First Cardiology Consultants, Ikoyi, Lagos, Nigeria; Department of Neurological Surgery, NYU Langone Health, New York, New York
12 shared publicationsMabel Banson
Department of Neurosurgery, Korle Bu Teaching Hospital, Accra, Ghana
7 shared publications- Bernice Limann
Department of Neurosurgery, Korle Bu Teaching Hospital, Accra, Ghana
5 shared publications - Pearl Ohenewaa Mbbs Tenkorang
University of Ghana Medical School, Accra, Ghana
5 shared publications Teddy Totimeh
Accra Medical Centre, Accra, Ghana
5 shared publications- Teddy Totimeh
Department of Neurological Surgery, Accra College of Medicine , Accra
5 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (5)
Early Reperfusion in Basilar Artery Occlusion Stroke Managed With Tenecteplase Versus Alteplase Before Endovascular Treatment
BACKGROUND: Timely reperfusion is a critical determinant of favorable outcomes in basilar artery occlusion (BAO) stroke. We aimed to examine whether the choice of thrombolytic agent predicts early reperfusion (ER) in BAO stroke managed with tenecteplase versus alteplase before endovascular treatment. METHODS: This was a retrospective, multicenter US cohort of consecutive patients with BAO from 14 stroke centers treated with tenecteplase or alteplase within 4.5 hours of last known well before endovascular treatment. The primary end point was ER, defined as angiographic ER (expanded Thrombolysis in Cerebral Infarction grade 2b to 3 on the first diagnostic angiogram), or clinical ER, defined as substantial neurological improvement precluding endovascular treatment and a good functional outcome (modified Rankin Scale score 0–3). RESULTS: Among 163 patients with BAO and a median last known well-to-needle time of 135 minutes (interquartile range, 100–193) and last known well-to-puncture time of 228 minutes (interquartile range, 166–307), ER was observed in 27 (16.6%) patients. Rates of ER were comparable between tenecteplase (14/75, 18.7%) and alteplase (13/88, 14.8%; adjusted odds ratio, 1.082 [95% CI, 0.444–2.631]; P =0.862). In addition, rates of angiographic ER and clinical ER subgroups did not differ between thrombolytic agents. Higher Basilar Artery on Computed Tomography Angiography scores and a nonatherothrombotic cause independently predicted ER. In multivariable analysis, a good functional outcome was associated with younger age, lower stroke burden, and shorter last known well-to-puncture time. CONCLUSIONS: In BAO treated within 4.5 hours of last known well, tenecteplase and alteplase produced comparable early reperfusion rates. Achieving ER did not modify the association between thrombolytic agent and good functional outcome, consistent with rapid thrombectomy in patients with no ER.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (5)
Open AccessEarly Reperfusion in Basilar Artery Occlusion Stroke Managed With Tenecteplase Versus Alteplase Before Endovascular Treatment
BACKGROUND: Timely reperfusion is a critical determinant of favorable outcomes in basilar artery occlusion (BAO) stroke. We aimed to examine whether the choice of thrombolytic agent predicts early reperfusion (ER) in BAO stroke managed with tenecteplase versus alteplase before endovascular treatment. METHODS: This was a retrospective, multicenter US cohort of consecutive patients with BAO from 14 stroke centers treated with tenecteplase or alteplase within 4.5 hours of last known well before endovascular treatment. The primary end point was ER, defined as angiographic ER (expanded Thrombolysis in Cerebral Infarction grade 2b to 3 on the first diagnostic angiogram), or clinical ER, defined as substantial neurological improvement precluding endovascular treatment and a good functional outcome (modified Rankin Scale score 0–3). RESULTS: Among 163 patients with BAO and a median last known well-to-needle time of 135 minutes (interquartile range, 100–193) and last known well-to-puncture time of 228 minutes (interquartile range, 166–307), ER was observed in 27 (16.6%) patients. Rates of ER were comparable between tenecteplase (14/75, 18.7%) and alteplase (13/88, 14.8%; adjusted odds ratio, 1.082 [95% CI, 0.444–2.631]; P =0.862). In addition, rates of angiographic ER and clinical ER subgroups did not differ between thrombolytic agents. Higher Basilar Artery on Computed Tomography Angiography scores and a nonatherothrombotic cause independently predicted ER. In multivariable analysis, a good functional outcome was associated with younger age, lower stroke burden, and shorter last known well-to-puncture time. CONCLUSIONS: In BAO treated within 4.5 hours of last known well, tenecteplase and alteplase produced comparable early reperfusion rates. Achieving ER did not modify the association between thrombolytic agent and good functional outcome, consistent with rapid thrombectomy in patients with no ER.
- Open Access
Trends in Treatment and Survival Among Patients with Glioblastoma in the United States from 2000 to 2020
Background: Population-level patterns in the real-world use of initial treatment combinations for glioblastoma (GBM) remain poorly characterized. Materials and Methods: We assessed temporal trends in treatment and survival among patients with GBM in the SEER registry. Guideline-concordant multimodal therapy was defined as cancer-directed surgery combined with radiotherapy and chemotherapy. Outcomes were further stratified by extent of resection, including gross total resection (GTR) versus subtotal resection. Results: Among 46,186 patients, 43.5% underwent GTR, 32.0% subtotal resection, and 24.5% no surgery; 71.8% received radiotherapy and 61.3% received chemotherapy. From 2000 to 2020, utilization increased for any surgery (OR/year 1.03, 95% CI 1.028–1.036), radiotherapy (1.01, 1.010–1.017), and chemotherapy (1.08, 1.081–1.088), whereas the likelihood of GTR vs. subtotal resection declined (0.92, 0.915–0.922). Triple therapy increased modestly (1.01, 1.005–1.012) but plateaued at 30%. Older age, non-lobar tumors, unmarried status, and lower income predicted lower odds of triple therapy; after adjustment, calendar year showed a marginal decline in the odds of receiving triple therapy (aOR/year 0.99, 0.99–1.00). Median overall survival improved from 6.0 to 10.0 months, with gains in fixed-time survival. Patients receiving multimodal therapy demonstrated the longest survival overall; within this group, GTR-based multimodal therapy was associated with longer survival than subtotal resection-based multimodal therapy across age strata. Conclusions: Guideline-concordant multimodal therapy was associated with the longest survival. GTR rates did not rise in recent years, and substantial disparities in the deployment of GTR-based multimodal therapy persisted. Efforts to expand equitable access and prioritize maximal safe resection are essential to achieve greater population-level survival gains. These differences should be interpreted cautiously, as SEER cannot distinguish appropriate clinical treatment selection from limited access to care or treatment ineligibility.
Open AccessTrends in Treatment and Survival Among Patients with Glioblastoma in the United States from 2000 to 2020
Background: Population-level patterns in the real-world use of initial treatment combinations for glioblastoma (GBM) remain poorly characterized. Materials and Methods: We assessed temporal trends in treatment and survival among patients with GBM in the SEER registry. Guideline-concordant multimodal therapy was defined as cancer-directed surgery combined with radiotherapy and chemotherapy. Outcomes were further stratified by extent of resection, including gross total resection (GTR) versus subtotal resection. Results: Among 46,186 patients, 43.5% underwent GTR, 32.0% subtotal resection, and 24.5% no surgery; 71.8% received radiotherapy and 61.3% received chemotherapy. From 2000 to 2020, utilization increased for any surgery (OR/year 1.03, 95% CI 1.028–1.036), radiotherapy (1.01, 1.010–1.017), and chemotherapy (1.08, 1.081–1.088), whereas the likelihood of GTR vs. subtotal resection declined (0.92, 0.915–0.922). Triple therapy increased modestly (1.01, 1.005–1.012) but plateaued at 30%. Older age, non-lobar tumors, unmarried status, and lower income predicted lower odds of triple therapy; after adjustment, calendar year showed a marginal decline in the odds of receiving triple therapy (aOR/year 0.99, 0.99–1.00). Median overall survival improved from 6.0 to 10.0 months, with gains in fixed-time survival. Patients receiving multimodal therapy demonstrated the longest survival overall; within this group, GTR-based multimodal therapy was associated with longer survival than subtotal resection-based multimodal therapy across age strata. Conclusions: Guideline-concordant multimodal therapy was associated with the longest survival. GTR rates did not rise in recent years, and substantial disparities in the deployment of GTR-based multimodal therapy persisted. Efforts to expand equitable access and prioritize maximal safe resection are essential to achieve greater population-level survival gains. These differences should be interpreted cautiously, as SEER cannot distinguish appropriate clinical treatment selection from limited access to care or treatment ineligibility.
- Open Access
- 18 August 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 138
Management of pediatric posterior fossa dermoid cysts: a systematic review and illustrative case report
Background: Dermoid cysts of the posterior fossa are less common congenital lesions that arise from ectodermal inclusions during neural tube closure. Their deep location in certain instances, as well as their slow growth, often delays diagnosis until symptoms from mass effect or rupture emerge. However, some posterior fossa dermoid cysts associated with dermal sinus tracts may present earlier, typically with recurrent infections. Materials and methods: We describe a child with a surgically managed posterior fossa dermoid cyst and present a systematic review of PubMed, ScienceDirect, and Scopus. Pediatric case reports and series were analyzed for demographics, presentation, imaging, surgical strategies, and outcomes. Results: Fifty-five studies (96 pediatric cases) met inclusion criteria. Of 86 patients with sex data, 54 (63%) were female. Common symptoms were hydrocephalus (49.6%, n = 34), headache (44.2%, n = 35), vomiting (38.2%, n = 34), and ataxia (24.5%, n = 22). CT (74.1%, n = 61) and MRI (65.2%, n = 47) were the main diagnostic tools, while earlier reports used radiographs (17.8%, n = 21). Suboccipital craniotomy was performed in 58 patients (84.7%). Gross total resection was achieved in 73.9% ( n = 55), subtotal in 24.1% ( n = 13). Cyst rupture occurred in 7 patients (10.9%). We report a 33-month-old female with vomiting, progressive ataxia, and dysphagia. MRI showed a midline posterior fossa lesion compressing the fourth ventricle and causing hydrocephalus. Gross total resection was achieved via suboccipital craniotomy, with uneventful recovery and symptom resolution at 3 months. Conclusion: Pediatric posterior fossa dermoid cysts, while less common, should be considered in the differential diagnosis of posterior fossa masses. Early recognition through characteristic imaging and meticulous surgical planning is vital for optimal outcomes. This review summarizes current evidence on the clinical features, imaging findings, surgical management and outcomes of pediatric posterior fossa dermoid cysts.
- 18 August 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 138
Open AccessManagement of pediatric posterior fossa dermoid cysts: a systematic review and illustrative case report
Background: Dermoid cysts of the posterior fossa are less common congenital lesions that arise from ectodermal inclusions during neural tube closure. Their deep location in certain instances, as well as their slow growth, often delays diagnosis until symptoms from mass effect or rupture emerge. However, some posterior fossa dermoid cysts associated with dermal sinus tracts may present earlier, typically with recurrent infections. Materials and methods: We describe a child with a surgically managed posterior fossa dermoid cyst and present a systematic review of PubMed, ScienceDirect, and Scopus. Pediatric case reports and series were analyzed for demographics, presentation, imaging, surgical strategies, and outcomes. Results: Fifty-five studies (96 pediatric cases) met inclusion criteria. Of 86 patients with sex data, 54 (63%) were female. Common symptoms were hydrocephalus (49.6%, n = 34), headache (44.2%, n = 35), vomiting (38.2%, n = 34), and ataxia (24.5%, n = 22). CT (74.1%, n = 61) and MRI (65.2%, n = 47) were the main diagnostic tools, while earlier reports used radiographs (17.8%, n = 21). Suboccipital craniotomy was performed in 58 patients (84.7%). Gross total resection was achieved in 73.9% ( n = 55), subtotal in 24.1% ( n = 13). Cyst rupture occurred in 7 patients (10.9%). We report a 33-month-old female with vomiting, progressive ataxia, and dysphagia. MRI showed a midline posterior fossa lesion compressing the fourth ventricle and causing hydrocephalus. Gross total resection was achieved via suboccipital craniotomy, with uneventful recovery and symptom resolution at 3 months. Conclusion: Pediatric posterior fossa dermoid cysts, while less common, should be considered in the differential diagnosis of posterior fossa masses. Early recognition through characteristic imaging and meticulous surgical planning is vital for optimal outcomes. This review summarizes current evidence on the clinical features, imaging findings, surgical management and outcomes of pediatric posterior fossa dermoid cysts.
- 25 July 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-13
Vaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trials
Background Glioblastoma remains highly lethal despite current standards, driving interest in vaccine-based immunotherapy to improve survival. Given variability in outcomes and uncertainty regarding optimal vaccine platforms, we conducted a time-to-event meta-analysis. Methods We conducted a database search for head-to-head phase II and III trials published through July 9, 2025, that assessed vaccine-based cancer immunotherapy in adults with newly diagnosed glioblastoma. Pseudo-individual data were digitized and reconstructed with the IPDfromKM method from survival curves. Primary endpoints of this study were overall survival (OS) and progression-free survival (PFS). This study was registered with PROSPERO, CRD420251231284. Results Initial search yielded 1248 articles, of which 5 randomized trials (696 patients: 358 vaccine and 338 control) met inclusion. Mean age ranged from 56.6–61.6 years, and 53.7% of participants had a Karnofsky Performance Status ≥ 90. In the primary analysis, vaccination did not significantly reduce the risk of death (HR 0.95; 95%CI 0.81–1.13) or disease progression (HR 0.96; 95%CI 0.82–1.12). In subgroup analyses, patients who underwent gross total resection and received vaccinations had improved OS compared with similarly resected controls (HR 0.50; 95%CI 0.31–0.81), and dendritic cell vaccines were associated with a PFS advantage (HR 0.73; 95%CI 0.56–0.96). Conclusion In this study, vaccinations did not significantly improve survival in adult patients with newly diagnosed glioblastoma. Gross total resection, however, seems to be associated with OS benefit of vaccinations. There is a need for more head-to-head clinical trials to supplement the available evidence.
- 25 July 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-13
Vaccine-based cancer immunotherapy in newly diagnosed glioblastoma: a time-to-event meta-analysis of phase II and III randomized controlled trials
Background Glioblastoma remains highly lethal despite current standards, driving interest in vaccine-based immunotherapy to improve survival. Given variability in outcomes and uncertainty regarding optimal vaccine platforms, we conducted a time-to-event meta-analysis. Methods We conducted a database search for head-to-head phase II and III trials published through July 9, 2025, that assessed vaccine-based cancer immunotherapy in adults with newly diagnosed glioblastoma. Pseudo-individual data were digitized and reconstructed with the IPDfromKM method from survival curves. Primary endpoints of this study were overall survival (OS) and progression-free survival (PFS). This study was registered with PROSPERO, CRD420251231284. Results Initial search yielded 1248 articles, of which 5 randomized trials (696 patients: 358 vaccine and 338 control) met inclusion. Mean age ranged from 56.6–61.6 years, and 53.7% of participants had a Karnofsky Performance Status ≥ 90. In the primary analysis, vaccination did not significantly reduce the risk of death (HR 0.95; 95%CI 0.81–1.13) or disease progression (HR 0.96; 95%CI 0.82–1.12). In subgroup analyses, patients who underwent gross total resection and received vaccinations had improved OS compared with similarly resected controls (HR 0.50; 95%CI 0.31–0.81), and dendritic cell vaccines were associated with a PFS advantage (HR 0.73; 95%CI 0.56–0.96). Conclusion In this study, vaccinations did not significantly improve survival in adult patients with newly diagnosed glioblastoma. Gross total resection, however, seems to be associated with OS benefit of vaccinations. There is a need for more head-to-head clinical trials to supplement the available evidence.
- 29 June 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 273
Impact of blood product removal versus temporary cerebrospinal fluid diversion on permanent shunting rates in posthemorrhagic hydrocephalus of prematurity: a comparative meta-analysis
Objective Intraventricular hemorrhage (IVH) is a major complication of extreme prematurity and a leading cause of posthemorrhagic hydrocephalus (PHH). Standard surgical treatment with temporary CSF diversion (TCD) for severe IVH often leads to permanent shunting and lifelong complications. This study compares blood product removal (BPR) and TCD only in reducing permanent cerebrospinal fluid (CSF) shunt dependence in preterm infants. Methods A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines to compare treatment outcomes (permanent CSF shunting, post-intervention CSF-related infections, secondary IVH, and mortality) in patients who underwent BPR versus TCD. Results Six studies involving 256 patients (128 patients in each treatment group) met inclusion criteria. Baseline demographics, including gestational age, birth weight, and IVH severity, were comparable between groups. BPR was associated with a lower risk of permanent shunting [RR: 0.67 (95% CI: 0.46–1.00) as compared to TCD (p = 0.047). The mean time to shunting was longer in the BPR group, but the difference was not statistically significant (79.6 vs 47.63 days; p = 0.267). TCD was associated with higher rates of CSF-related infections (26.54% vs 2.40%; p = 0.019) and mortality (19.27% vs 3.47%; p = 0.007). Conclusion BPR was associated with a lower risk of permanent shunting and lower rates of mortality and CSF-related infections compared to TCD. While BPR presents a promising alternative to conventional TCD approaches, further studies are needed to validate these findings.
- 29 June 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 273
Impact of blood product removal versus temporary cerebrospinal fluid diversion on permanent shunting rates in posthemorrhagic hydrocephalus of prematurity: a comparative meta-analysis
Objective Intraventricular hemorrhage (IVH) is a major complication of extreme prematurity and a leading cause of posthemorrhagic hydrocephalus (PHH). Standard surgical treatment with temporary CSF diversion (TCD) for severe IVH often leads to permanent shunting and lifelong complications. This study compares blood product removal (BPR) and TCD only in reducing permanent cerebrospinal fluid (CSF) shunt dependence in preterm infants. Methods A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines to compare treatment outcomes (permanent CSF shunting, post-intervention CSF-related infections, secondary IVH, and mortality) in patients who underwent BPR versus TCD. Results Six studies involving 256 patients (128 patients in each treatment group) met inclusion criteria. Baseline demographics, including gestational age, birth weight, and IVH severity, were comparable between groups. BPR was associated with a lower risk of permanent shunting [RR: 0.67 (95% CI: 0.46–1.00) as compared to TCD (p = 0.047). The mean time to shunting was longer in the BPR group, but the difference was not statistically significant (79.6 vs 47.63 days; p = 0.267). TCD was associated with higher rates of CSF-related infections (26.54% vs 2.40%; p = 0.019) and mortality (19.27% vs 3.47%; p = 0.007). Conclusion BPR was associated with a lower risk of permanent shunting and lower rates of mortality and CSF-related infections compared to TCD. While BPR presents a promising alternative to conventional TCD approaches, further studies are needed to validate these findings.
- 30 May 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103127
Estimating overall survival for breast cancer in Ghana: A time-to-event meta-analysis
- 30 May 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103127
Estimating overall survival for breast cancer in Ghana: A time-to-event meta-analysis
- 13 February 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (5) , 108592
Establishing an Interventional Radiology Service for Intracranial Aneurysms: Early Outcomes from Nigeria’s First Cohort
- 13 February 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (5) , 108592
Establishing an Interventional Radiology Service for Intracranial Aneurysms: Early Outcomes from Nigeria’s First Cohort
- 13 February 2026
- Published by Springer Nature in European Spine Journal
- Vol. 35 (8) , 1-10
Impact of adjunctive spine surgery on multilevel spinal fusion in the management of adult spinal deformity: A single centre propensity score-matched analysis
- 13 February 2026
- Published by Springer Nature in European Spine Journal
- Vol. 35 (8) , 1-10
Impact of adjunctive spine surgery on multilevel spinal fusion in the management of adult spinal deformity: A single centre propensity score-matched analysis
- 11 February 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 68
Treatment failure after endoscopic third ventriculostomy with choroid plexus cauterization, endoscopic third ventriculostomy alone, and ventriculoperitoneal shunt in congenital hydrocephalus: a network and time-to-event meta-analysis
Congenital hydrocephalus is commonly treated with endoscopic third ventriculostomy (ETV), ETV with choroid plexus cauterization (ETV + CPC), or ventriculoperitoneal shunting (VPS), yet outcomes vary, and treatment failure is frequent. This study examines treatment failure between procedures in patients with congenital hydrocephalus. We conducted a database search from inception to February 2025 for head-to-head studies comparing the primary treatments. A network meta-analysis (NMA) was employed to assess failure rates, and pseudo-individual patient data from published Kaplan-Meier (KM) curves were used to evaluate time to failure. This study was registered with PROSPERO (CRD420251142532). The initial search identified 851 articles, of which eight studies (402 patients; 155 VPS, 175 126 only and 121 ETV + CPC) were included. Aqueductal stenosis was the most frequent etiology in ETV only (68.3%) and ETV + CPC groups (51.0%). Myelomeningocele-related hydrocephalus was most reported in the ETV + CPC group (28.9%). Treatment failure was reported at 35.5% in the VPS group, 31.4% for ETV + CPC and 23.8% for ETV only. ETV + CPC demonstrated a significantly lower risk of failure compared with VPS (RR = 0.43, 95% CI: 0.19-0.99). Surface under the cumulative ranking curve analysis ranked ETV + CPC as the most effective strategy in minimizing treatment failure (Rank 1: 88.9%). In KM analysis, the median failure-free survival was not reached in the ETV + CPC group, but was 57.3 months for ETV only and 19.8 months for VPS. ETV + CPC ranked best in reducing treatment failure with significant benefits over VPS. Larger studies are required to clarify the comparative efficacy of treatment modalities and to identify surgical and etiological factors predictive of treatment failure.
- 11 February 2026
- Published by Springer Nature in Child's Nervous System
- Vol. 42 (1) , 68
Treatment failure after endoscopic third ventriculostomy with choroid plexus cauterization, endoscopic third ventriculostomy alone, and ventriculoperitoneal shunt in congenital hydrocephalus: a network and time-to-event meta-analysis
Congenital hydrocephalus is commonly treated with endoscopic third ventriculostomy (ETV), ETV with choroid plexus cauterization (ETV + CPC), or ventriculoperitoneal shunting (VPS), yet outcomes vary, and treatment failure is frequent. This study examines treatment failure between procedures in patients with congenital hydrocephalus. We conducted a database search from inception to February 2025 for head-to-head studies comparing the primary treatments. A network meta-analysis (NMA) was employed to assess failure rates, and pseudo-individual patient data from published Kaplan-Meier (KM) curves were used to evaluate time to failure. This study was registered with PROSPERO (CRD420251142532). The initial search identified 851 articles, of which eight studies (402 patients; 155 VPS, 175 126 only and 121 ETV + CPC) were included. Aqueductal stenosis was the most frequent etiology in ETV only (68.3%) and ETV + CPC groups (51.0%). Myelomeningocele-related hydrocephalus was most reported in the ETV + CPC group (28.9%). Treatment failure was reported at 35.5% in the VPS group, 31.4% for ETV + CPC and 23.8% for ETV only. ETV + CPC demonstrated a significantly lower risk of failure compared with VPS (RR = 0.43, 95% CI: 0.19-0.99). Surface under the cumulative ranking curve analysis ranked ETV + CPC as the most effective strategy in minimizing treatment failure (Rank 1: 88.9%). In KM analysis, the median failure-free survival was not reached in the ETV + CPC group, but was 57.3 months for ETV only and 19.8 months for VPS. ETV + CPC ranked best in reducing treatment failure with significant benefits over VPS. Larger studies are required to clarify the comparative efficacy of treatment modalities and to identify surgical and etiological factors predictive of treatment failure.